The United States market has shown robust performance, climbing 3.1% over the last week and 27% over the past year, with earnings projected to grow by 16% annually. In this context of market growth, identifying stocks with strong financials can be crucial for investors seeking potential opportunities. Penny stocks, though often seen as a term from earlier market days, still represent a segment where smaller or newer companies might offer both affordability and significant growth potential.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
WM Technology (MAPS)	$0.3921	$67.77M	✅ 3 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.21	$371.86M	✅ 3 ⚠️ 2 View Analysis >
Tuya (TUYA)	$2.33	$1.41B	✅ 4 ⚠️ 1 View Analysis >
FinVolution Group (FINV)	$4.95	$1.25B	✅ 4 ⚠️ 1 View Analysis >
Tuniu (TOUR)	$0.7144	$82.89M	✅ 2 ⚠️ 2 View Analysis >
Information Services Group (III)	$3.11	$187.84M	✅ 3 ⚠️ 1 View Analysis >
Niagen Bioscience (NAGE)	$4.50	$361.11M	✅ 3 ⚠️ 1 View Analysis >
LifeVantage (LFVN)	$4.15	$53.14M	✅ 4 ⚠️ 3 View Analysis >
SIGA Technologies (SIGA)	$7.80	$312.37M	✅ 2 ⚠️ 1 View Analysis >
BAB (BABB)	$0.895	$6.5M	✅ 2 ⚠️ 3 View Analysis >

We'll examine a selection from our screener results.

Akebia Therapeutics (AKBA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for kidney disease patients, with a market cap of approximately $375.03 million.

Operations: The company generates $236.20 million in revenue from its segment focused on developing and commercializing innovative therapeutics.

Market Cap: $375.03M

Akebia Therapeutics, with a market cap of US$375.03 million, has shown significant revenue growth, reporting US$236.2 million for 2025 compared to US$160.18 million the previous year, while reducing its net loss from US$69.41 million to US$5.35 million over the same period. Despite being unprofitable and having a high debt-to-equity ratio of 598.7%, Akebia maintains a positive free cash flow and sufficient cash runway for over three years if current conditions persist. Recent board changes include the appointment of Dr. Philip J. Vickers, bringing extensive biopharmaceutical experience to enhance strategic direction and innovation efforts.

SNDL (SNDL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SNDL Inc. operates in the production, distribution, and sale of cannabis products for the adult-use market both in Canada and internationally, with a market cap of approximately $368.07 million.

Operations: SNDL generates revenue from three main segments: Liquor Retail (CA$539.63 million), Cannabis Retail (CA$330.24 million), and Cannabis Operations (CA$144.66 million).

Market Cap: $368.07M

SNDL Inc., with a market cap of approximately $368.07 million, operates in the cannabis sector and has shown resilience despite being unprofitable. The company reported CA$946.4 million in sales for 2025, reducing its net loss to CA$15.77 million from CA$94.8 million the previous year, indicating improved financial management. SNDL's strong liquidity position is evident as its short-term assets significantly exceed liabilities, and it remains debt-free with a cash runway exceeding three years due to positive free cash flow growth of 53.7% annually. Recent leadership changes include Ryan Hellard stepping in as Interim President of Cannabis following Tyler Robson's departure.

Treace Medical Concepts (TMCI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Treace Medical Concepts, Inc. is a medical technology company that designs, manufactures, and markets medical devices in the United States with a market cap of $116.96 million.

Operations: The company generates revenue of $212.69 million from its activities in designing, manufacturing, and marketing medical devices.

Market Cap: $116.96M

Treace Medical Concepts, Inc., with a market cap of US$116.96 million, faces challenges as it remains unprofitable and its net losses have widened over the past year. Despite this, the company has maintained a satisfactory debt level with a net debt to equity ratio of 10.3% and possesses sufficient cash runway for over a year based on current free cash flow trends. Recent product innovations like the SuperBite Compression Screw System are poised for commercialization in late 2026, potentially expanding their addressable market by US$300 million, which could bolster future revenue streams amidst declining sales projections for 2026.

Key Takeaways

• Jump into our full catalog of 361 US Penny Stocks here.
• Ready For A Different Approach? Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.